National Institutes of Health: Gliosarcoma trials

The registry lists 81 Gliosarcoma studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 45 have results posted.

Phase 1 47Phase 2 53Phase 3 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent GlioblastomaNot yet recruitingNCT07422363Phase 1
• Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated GlioblastomaCompletedNCT04396860Phase 2/3Results posted
• Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed GlioblastomaActive, not recruitingNCT04216329Phase 1Results posted
• Sunitinib in Sarcomas of the Central Nervous SystemTerminatedNCT03641326Phase 2Results posted
• Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and GlioblastomaTerminatedNCT02942264Phase 1/2Results posted
• Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeActive, not recruitingNCT02152982Phase 2/3Results posted
• Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior BevacizumabCompletedNCT01931098Phase 2Results posted
• Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine GliomasCompletedNCT01922076Phase 1Results posted
• Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT01648348Phase 1/2Results posted
• Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory SarcomaCompletedNCT01614795Phase 2Results posted
• Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain TumorsCompletedNCT01609790Phase 2Results posted
• Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine GliomasCompletedNCT01514201Phase 1/2Results posted
• CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIIICompletedNCT01454596Phase 1/2Results posted
• Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine GliomaCompletedNCT01189266Phase 1/2Results posted
• RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant GliomaTerminatedNCT01189240Phase 1/2Results posted
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive GlioblastomaTerminatedNCT01122901Phase 2Results posted
• Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT01062425Phase 2Results posted
• Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT01051557Phase 1/2Results posted
• A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade GliomasCompletedNCT00995007Phase 2Results posted
• GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by SurgeryCompletedNCT00980343Phase 2Results posted
• MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00902577Phase 2Results posted
• Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT00884741Phase 3Results posted
• Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00731731Phase 1/2Results posted
• Tandutinib Plus Bevacizumab to Treat Recurrent Brain TumorsCompletedNCT00667394Phase 2Results posted
• Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma MultiformeCompletedNCT00641706Phase 2Results posted
• Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCompletedNCT00540722Phase 2Results posted
• Sunitinib in Treating Patients With Recurrent Malignant GliomasCompletedNCT00499473Phase 2Results posted
• Pazopanib in Treating Patients With Recurrent GlioblastomaCompletedNCT00459381Phase 2Results posted
• Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCompletedNCT00445588Phase 2Results posted
• Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or GliosarcomaCompletedNCT00433381Phase 2Results posted
• Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaCompletedNCT00423735Phase 2Results posted
• Tandutinib in Treating Patients With Recurrent or Progressive GlioblastomaCompletedNCT00379080Phase 1/2Results posted
• VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to TemozolomideCompletedNCT00369590Phase 2Results posted
• Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaCompletedNCT00335764Phase 1/2Results posted
• Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent GlioblastomaCompletedNCT00329719Phase 1/2Results posted
• Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT00305864Phase 1/2Results posted
• Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCompletedNCT00238303Phase 2Results posted
• Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma MultiformeTerminatedNCT00112866Phase 2Results posted
• Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant GliomaCompletedNCT00112736Phase 1/2Results posted
• Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System TumorsCompletedNCT00095940Phase 1/2Results posted
• FR901228 in Treating Patients With Recurrent High-Grade GliomasCompletedNCT00085540Phase 1/2Results posted
• Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00085254Phase 1/2Results posted
• A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade GliomasCompletedNCT00045708Phase 1/2Results posted
• Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive MeningiomaCompletedNCT00045110Phase 1/2Results posted
• Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed GliomasCompletedNCT00042991Phase 1/2Results posted
• Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBMCompletedNCT00004146Phase 2Results posted
• Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT04817254Phase 2
• Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain CancerTerminatedNCT03107780Phase 1
• Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent GlioblastomaCompletedNCT02709226Phase 1
• Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT02311920Phase 1
• Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT02227901Phase 1
• Sapanisertib Before and After Surgery in Treating Patients With Recurrent GlioblastomaTerminatedNCT02133183Phase 1
• Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade GliomaCompletedNCT02101905Phase 1
• High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent GliomaTerminatedNCT01378481Phase 1
• RO4929097 in Treating Patients With Recurrent Invasive GliomasTerminatedNCT01269411Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma MultiformeTerminatedNCT01122888Phase 1
• RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT01119599Phase 1
• Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent GlioblastomaCompletedNCT00979862Phase 1
• Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT00662506Phase 1/2
• Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant GliomaCompletedNCT00650923Phase 1
• Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant GliomaTerminatedNCT00430079Not applicable
• Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00316849Phase 1
• AZD2171 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00305656Phase 2
• Vorinostat and Temozolomide in Treating Patients With Malignant GliomasActive, not recruitingNCT00268385Phase 1
• Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain TumorsTerminatedNCT00110032Phase 1
• GW572016 to Treat Recurrent Malignant Brain TumorsCompletedNCT00107003Phase 2
• Sorafenib in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00093613Phase 1
• Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma MultiformeTerminatedNCT00075491Phase 2
• Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00058097Phase 2
• Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma MultiformeCompletedNCT00052208Phase 1/2
• Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT00049387Phase 1
• Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT00045565Phase 1
• Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain TumorsCompletedNCT00039494Phase 2
• Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research ProtocolsTerminatedNCT00035373
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• CCI-779 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00016328Phase 2
• Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00014170Phase 2
• Bortezomib in Treating Patients With Recurrent GliomaTerminatedNCT00006773Phase 1
• Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma MultiformeTerminatedNCT00005856Phase 1/2
• Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma MultiformeCompletedNCT00004262Phase 1